

**CLEAN COPY OF CLAIMS**

1. A solid formulation based
  - i) on lipid acid or a physiologically acceptable salt thereof and, where appropriate, other active substancesand a formulation base having
  - ii) a binder component; and
  - iii) where appropriate, other physiologically acceptable excipients,wherein lipid acid or a physiologically acceptable salt thereof is in the form of a molecular dispersion.
2. A formulation as claimed in claim 1, wherein at least one binder of the binder component is selected from polyvinylpyrrolidones, N-vinylpyrrolidone copolymers, cellulose derivatives and modified starches.
3. A formulation as claimed in claim 1, wherein the binder component has a glass transition temperature of more than 80°C, preferably of more than 90° and in particular more than 100°.
4. A formulation as claimed in claim 1, wherein the formulation comprises
  - i) 1 to 60% by weight, preferably 5 to 35% by weight and in particular 10 to 30% by weight of active substance component;
  - ii) 20 to 99% by weight, preferably 30 to 90% by weight and in particular 40 to 80% by weight, of binder component;
  - iii) 0 to 91% by weight, preferably 1 to 60% by weight and in particular 5 to 40% by weight, of other physiologically acceptable excipients;

202209090800T

112

5. A formulation as claimed in claim 1, wherein the content of active substance component relative to binder component is from 1 to 50% by weight, preferably 10 to 40% by weight and in particular 20 to 30% by weight.
6. A formulation as claimed in claim 1, comprising
  - i) lipid acid or a physiologically acceptable salt thereof;
  - ii) at least one binder selected from polyvinylpyrrolidones, –vinylpyrrolidone/vinyl acetate copolymers, hydroxypropyl-cellulose, hydroxypropylmethylcelluloses and modified starches; and
  - iii) where appropriate other physiologically acceptable excipients, in particular a flow regulator, e.g. highly disperse silica gel.
7. A formulation as claimed in claim 1 by melt extrusion of a mixture comprising lipid acid or a physiologically acceptable salt thereof, binder and, where appropriate, other active substances and/or other physiologically acceptable excipients.
8. A method for oral administration of lipid acid or of a physiologically acceptable salt thereof, comprising administering a formulation as claimed in claim 1, where appropriate with the addition of other excipients as dosage form.

20221010 09:08:00

We claim:

1. A solid formulation based
- 5
- i) on lipoic acid or a physiologically acceptable salt thereof and, where appropriate, other active substances
- and a formulation base having
- 10
- ii) a binder component; and
- iii) where appropriate, other physiologically acceptable excipients,
- 15
- wherein lipoic acid or a physiologically acceptable salt thereof is in the form of a molecular dispersion.
2. A formulation as claimed in claim 1, wherein at least one
- 20
- binder of the binder component is selected from polyvinylpyrrolidones, N-vinylpyrrolidone copolymers, cellulose derivatives and modified starches.
3. A formulation as claimed in claim 1, wherein the binder
- 25
- component has a glass transition temperature of more than 80°C, preferably of more than 90°C and in particular of more than 100°C.
4. A formulation as claimed in claim 1, wherein the formulation
- 30
- comprises
- i) 1 to 60% by weight, preferably 5 to 35% by weight and in particular 10 to 30% by weight of active substance component;
- 35
- ii) 20 to 99% by weight, preferably 30 to 90% by weight and in particular 40 to 80% by weight, of binder component;
- 40
- iii) 0 to 91% by weight, preferably 1 to 60% by weight and in particular 5 to 40% by weight, of other physiologically acceptable excipients;

5. A formulation as claimed in claim 1, wherein the content of active substance component relative to binder component is from 1 to 50% by weight, preferably 10 to 40% by weight and in particular 20 to 30% by weight.
- 5 6. A formulation as claimed in claim 1, comprising
- 10 i) lipoic acid or a physiologically acceptable salt thereof;
- 15 ii) at least one binder selected from polyvinylpyrrolidones, N-vinylpyrrolidone/vinyl acetate copolymers, hydroxypropyl-celluloses, hydroxypropylmethylcelluloses and modified starches; and
- 20 iii) where appropriate other physiologically acceptable excipients, in particular a flow regulator, e.g. highly disperse silica gel.
- 25 7. A formulation as claimed in any of the preceding claims, obtainable by melt extrusion of a mixture comprising lipoic acid or a physiologically acceptable salt thereof, binder and, where appropriate, other active substances and/or other physiologically acceptable excipients.
- 30 8. A method for oral administration of lipoic acid or of a physiologically acceptable salt thereof, comprising administering a formulation as claimed in any of claims 1 to 7, where appropriate with the addition of other excipients, as dosage form.
- 35
- 40
- 45

"005220" 8990800T